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Prostate cancer is the second most common cancer in men and acording to the Globocan report from 
2012, there will be over 1.2 million new cases and over 300 000 deaths, worldwide. Organ-defined 
prostate cancer is a curable disease, but then it develops into metastatic castration resistant prostate 
cancer, and it is usually a matter of time until the patient develops resistance to chemotherapy and 
becomes an incurable disease.  
This evokes the need for biomarkers that can predict disease progression and response to therapy. This 
would allow for a better stratification of the patients to receive the most efficacious, therapeutic  
treatment. Cancer cell derived exosomes, with their molecular cargo that represents the tumor cells, 
have been demonstrated to be a good source of such prognostic and predictive biomarkers. In this 
study we isolated and characterized exosomes derived from prostate cancer cells that are resistant to 
docetaxel and abiraterone acetate. One interesting finding is that the cells that are resistant to these two 
drugs secrete more exosomes than their sensitive counterparts. We compared the proteomic profile of 
these exosomes with exosomes from the parental, drug-sensitive cell lines. We have identified a 
number of putative markers that may constitute a predictive signature and are currently under 
validation. From our pilot studies we have identified that p-gp positive exosomes may function as 
predictive biomarkers for response to docetaxel, and that exosomes containing the splice variant 7 of 
the androgen receptor may have the potential to predict response to abiraterone acetate and 
enzalutamide. However, both of these biomarkers have to be validated in larger patient cohorts along 
with the newly identified proteins. In addition to proteomics, the exosomes are currently being 
analysed by transcriptomics, mRNA and miRNA arrays. These combined molecular data will provide 
valuable information in finding predictive signatures for response to therapy, in order to provide the 













ABSTRACT (IN PORTUGUESE) 
 
 
Em termos mundiais, o cancro da prostata é o segundo cancro com maior incidência no homem, e 
segundo o relatório de 2012 da Globocan, estão previstos 1.2 milhões de novos casos incidentes e mais 
de 300 mil mortes. Quando o cancro da próstata passa a uma fase resistente à deprivação hormonal e 
com potencial de criar metástases, é só uma questão de tempo até o doente apresentar resistência à 
quimioterapia, tornando-se incurável. 
Isto levanta uma questâo importante: a necessidade de descobrir biomarcadores que possam prever a 
progressão da doença e a resposta a determinados fármacos. Tal descoberta iria permitir uma melhor 
estratificação dos doentes para que pudessem ter um cuidado médico mais apropriado, nomeadamente 
ao nível quimioterapêutico. Exosomas isolados de células tumorais possuem um perfil molecular 
equiparado ao do tumor, o que faz com que estes tenham o potencial de serem ou conterem esses 
mesmos biomarcadores. Neste estudo isolámos e caracterizámos exosomas provenientes de células do 
cancro da próstata, células estas que apresentam resistência aos fármacos Docetaxel e Abiraterone 
Acetate. Uma observação relevante é o facto de as células resistentes a estes dois fármacos excretarem 
mais exosomas do que as mesmas células mas sensíveis aos fármacos, o que revela o potencial dos 
exosomas em serem utilizados como biomarcadores. Comparámos o proteoma destes exosomas com 
exosomas provenientes das linhas celulares não resistentes, e identificámos um conjunto de proteínas 
que se encontram actualmente em estudo relativamente ao seu potencial como biomarcador. Nos 
nossos estudos iniciais identificámos: exosomas que contêm a proteina p-gp, que podem servir como 
biomarcador de resposta ao tratamento com docetaxel; e exosomas que contêm proteinas proveniente 
do splicing alternativo 7 do receptor de androgénio, como tendo o potencial para prever uma resposta 
aos fármacos abiraterone acetate e enzalutamide. No entanto, tanto estes biomarcadores como as 
proteínas recentemente identificadas  necessitam de posterior validação em grandes grupos de doentes. 
Para além do proteoma seria beneficial obter o perfil genómico (mRNA e miRNAS) destes exosomas. 
Ao complementar as duas abordagens poderíamos obter informação relevante para identificar 
assinaturas com potencial de prever a resposta à quimioterapia, com o objectivo de providenciar aos 
doentes um atendimento médico mais personalizado e estratificado relativamente às opções de 
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 Cancer is the second leading cause of death worldwide, accounting for over 8 million deaths in 
2013 (Global Burden of Disease Cancer et al., 2015). Despite the progress made within the recent years 
regarding prevention, diagnosis and treatment of certain types of cancer, close to 15 million incident 
cancer cases were reported in 2013. These numbers are attributed not only to risk factors such as 
smoking, obesity and dietary habits, but also to a global increase in the world's population and 
respective life expectancy. While these numbers seem alarming, they are suspected to increase to 22 
million new cases within the next 20 years (Edwards et al., 2014, Global Burden of Disease Cancer et al., 
2015). 
  
But what is cancer?  
The majority of the cells in our body have the ability to grow, divide and die. Ultimately speaking it 
seems that there is no life without death, and our survival is dependent on the balance between a 
sustained cell proliferation and programmed cell death. In a simplistic view, cancer can be seen as 
something that disrupts the balance of life, where cells no longer respond to the strict mechanisms that 
regulate cell survival, proliferation and death. But it is much more complex than that, and even though 
research has provided answers to many questions, it seems that we are still only scratching the surface. 
Let’s have a brief overview of this complexity. 
 
 1.1.1 Tumourigenesis 
   
Cancer is a multifactorial disease, with its progression being influenced by genetic, epigenetic and 
environmental factors (Lochhead et al., 2015). These factors can alter the content and structure of a cell's 
genome, which can lead to atypical cell phenotypes. Mutated genes often prompt changes in cellular 
growth programs, resulting in the formation of large cell populations, thus breaking tissue 
homeostasis. These masses of cells can be divided into two major categories, based on their ability to 
invade neighbouring tissue: benign tumours, which grow locally and do not metastasize, and 
malignant tumours that can invade not only nearby tissues but also metastasize to distant organs 





 1.1.2 Tumour Progression 
 
While most of the tumours originating in humans are benign and cause little harm to the host, there are 
cases where the tumour mass applies pressure into vital organs, with one example being the brain. In 
addition, some benign tumours can develop into dysplasias. These are characterized by abnormal cells 
and additional effects on the overall tissue architecture, as opposed to hyperplasias, characterized by 
an over excessive cell proliferation but no apparent anomaly in the tissue architecture. Added degrees 
of abnormality can further develop dysplasias into neoplasias, which can be pre-malignant or 
malignant, and it's the latter that is collectively termed as cancer (Shin et al., 2014). A simplified 







 1.1.3 Stratification and "Drivers" of Cancer 
 
Cancer can be considered as the collective name for many different types of malignancy. Stratification 
can be done based on the cellular origin of the tumour, with malignant tumours originating from 
epithelial cells, being the most common. These are termed carcinomas, but more than 100 different 
types exist. Other common examples include sarcomas, formed from mesenchymal cells in soft 
tissues; leukemias, lymphomas and multiple myelomas, originating from haematological cells which 
do not form solid tumours, but rather consist of malignant cells present in the blood or the lymphatic 
system, initiating in different kinds of immune cells; and many others such as melanomas and 
neuronal tumours (Chizuka et al., 2006). 
 
Types of cancer are also named after the organ or tissue in which they appear, but can also be 
characterized by the types of genetic alterations that are thought to be driving them. These genetic 
Figure 1. Tumour initiation and progression. Simplified schematics of malignant neoplasia 
formation from normal tissue. Adapted from http://www.cancer.gov/about-cancer/what-is-cancer 
on September the 18th, 2015. 
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modifications, commonly called "drivers" of cancer, usually affect three main types of genes: proto-
oncogenes, tumour suppressor genes and DNA repair genes (Vogelstein and Kinzler, 2004). The most 
common genetic events that initiate cancer are: copy number amplification or specific mutations that 
might activate proto-oncogenes into cancer-driving genes, also known as oncogenes, which are 
involved in cell growth, division and death, allowing cells to survive when they were not supposed to; 
there are also deletions, mutations and epigenetic events that can cause loss of function of certain 
genes, namely tumour suppressor genes, with p53 as the most prevalent example, allowing cells to 
divide in an uncontrolled manner, when otherwise it would act by supressing the proliferation and 
survival of affected cells. These events usually occur simultaneously, while also affecting DNA repair 
genes, which may cause an accumulation of mutations in these and other genes, potentially leading to 
the development of cancer. 
 
 1.1.4 Hallmarks of Cancer 
 
Cancer usually develops over many years, starting from relatively benign agglomerations of cells and 
then turning into malignant tumours. The accumulation of these genetic alterations over the years can 
lead to the acquisition of a specific set of properties that account for the transition from normal to 
malignant cells. During tumour progression, most malignant tumours acquire the same set of 
functional capabilities, regardless of tumour origin, coined as "Hallmarks of Cancer" by Hanahan and 
Weinberg. These consistently observed characteristics displayed by cancer cells are: sustained 
proliferative signalling, evasion of growth suppression, activation of invasion and metastasis, 
replicative immortality, induction of angiogenesis, and resisting cell death; (Hanahan and Weinberg, 
2000). 
 
Within the last decade, cancer research has broadened the concept that primary tumours are merely a 
collection of abnormally proliferating cancer cells. Aspects of tumour microenvironment and tissue 
architecture have been included, as well as the presence of cancer stem cells, the influence of the 
immune system, and how cancer cells manipulate energy metabolism in the tumour sites. Two 
emerging hallmarks - avoiding immune destruction and deregulating cellular energetics -, plus two 
new enabling characteristics - genomic instability and mutation, and tumour-promoting inflammation - 
that assist in the development of the other components, have been added to the panel of the 

























 1.2 PROSTATE CANCER  
  
 1.2.1 The Prostate 
 
The prostate is a walnut-sized gland that can only be found 
in men; it is located in front of the rectum and below the 
bladder, surrounding the urethra. Its main function is the 
production of seminal fluid, mostly produced in the 
seminal vesicles located behind the prostate, which has a 
protective and supportive role in transporting sperm 
(Hurwitz et al., 2003). The prostate is highly dependent on 
androgens, such as the male hormones testosterone and 
dihydrotestosterone (DHT), and its size changes with age. 
It grows rapidly during puberty, due to an increased 
concentration of these hormones in the body, and it usually 
stays about the same size in adult men, as long as male 
hormones are present.  
  
 
Figure 3. The prostate. Schematic representation of 
the prostate gland (with a malignant tumour), a 
seminal vesicle, the urethra and the bladder. Adapted 
from  
http://www.cancer.org/cancer/prostatecancer/detailedg
uide/prostate-cancer-what-is-prostate-cancer on the 
September 18th, 2015. 
Figure 2. The Hallmarks of Cancer. Overview of common characteristics of malignant neoplasias, 
including two emerging hallmarks - avoiding immune destruction and deregulating cellular energetics-, and 
two enabling characteristics - genome instability and mutation and tumour-promoting inflammation-. 





If the prostate continues to grow, which often happens, specially in old men, it can lead to a common 
condition named benign prostatic hyperplasia (BPH). BPH can be a serious problem for some men, 
but it is not cancer. Similarly, abnormal prostate development can lead to other conditions, such as 
prostatic intraepithelial neoplasia (PIN), or proliferative inflammatory atrophy (PIA), and even though 
the concept is not fully understood, research suggests that PCa can arise from one of these pre-
cancerous conditions. Adenocarcinoma represents the most common form of PCa, with 70 to 80 % of 
cases arising in the peripheral zone of the prostate gland (DeMarzo et al., 2003, Liu et al., 2015). 
 
 1.2.2 Epidemiology 
 
According to a GLOBOCAN report published in 2012, it is predicted that in 2015, there will be over 
300 000 deaths and 1.2 million new cases of PCa, comprising approximately 15% of all cancers 
diagnosed in men worldwide. This makes PCa the second most common cancer and the fifth leading 
cause of cancer-related deaths in men worldwide. However, if we only consider the more developed 
countries, PCa ranks first and third respectively (Ferlay et al., 2015). 
 
 1.2.3 Risk Factors 
 
PCa is one of the main medical conditions afflicting male populations around the world, and when it 
comes to assessing the risk factors that are associated to PCa, the convergence is on age and family 
history. Regarding the incidence of PCa, it increases dramatically in men over 60 years old, and peaks 
in men over 75 years old. Another interesting fact is that PCa was never observed in men younger than 
15 years of age, hinting for the critical role of androgens in PCa development (Ferlay et al., 2015). 
Concerning family history, the risk for PCa is at least two fold higher if one first-line relative 
manifested the disease, and there is a 5 to 11-fold increase in the risk if there are two or more first-line 
relatives with history of prostate cancer (Grönberg et al., 1996). This points to a hereditary form of PCa, 
and several susceptibility genes have been identified, though none of them show high penetrance. A 
few examples are: namely hereditary prostate cancer 1 (HPC-1), breast cancer 1/2 (BRCA1/2), 
homeobox B13 (HOXB13), Nijmegen breakage syndrome 1 (NBS1), checkpoint kinase 2 (CHEK2), 
PALB2, among others (Eeles et al., 2014, Mazaris and Tsiotras, 2013).   
 
The correlation between the genetic variants of these and other genes with PCa needs to be further 
investigated, as most of them show low frequency in the population at-risk, which is why the fusion 
protein TMPRSS2-ERG, originating from two oncogenes, seems of particular interest, considering the 
high frequency shown. When coupled to the loss of PTEN and concomitant activation of AKT, this 
fusion protein acts on downstream pathways to promote PCa progression (Squire, 2009). Other factors 
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Figure 4. TMPRSS2-ERG fusion protein. Loss of PTEN may act with the TMPRSS2-ERG fusion protein leading to PCa 
progression. PIN - prostatic intraepithelial neoplasia; ARE - androgen receptor elements; TA - transcriptional activators; TF - 
transcription factors. Taken from Squire, J. 2009. TMPRSS2-ERG and PTEN loss in prostate cancer. Nature Genetics 41: 509-510. 
 
include race, physical activity, diet, smoking and sexual activity (Patel and Klein, 2009). Therefore, it 
seems that hereditary factors are crucial in determining the risk of developing clinical PCa, but 
exogenous factors may have an important impact on this risk. The doubt dwells on whether there is 
enough evidence to recommend changes in the patients’ lifestyle that would decrease the risk, 

















 1.2.4 From Screening to Diagnosis and Classification  
 
Early detection of PCa is crucial for the patients’ outcome, and screening approaches are usually 
performed on asymptomatic but at risk patients. These are based on serum prostate-specific antigen 
(PSA) levels coupled with digital rectal examination (Smith et al., 2007).  
 
Men with elevated PSA levels that show a free-to-total PSA ratio of less than 20%, and also present a 
PSA velocity higher than 0.75 ng/mL/year, have higher risk of developing PCa. In this situation, 
transrectal ultrasound guided biopsy of the prostate is recommended, being the main diagnostic tool 
used in the clinic (Heidenreich et al., 2014a). 
 
Classification of PCa is based on the Gleason score, with higher values predicting a more rapid 
progression of the tumour, suggesting a need for more aggressive treatments. This score ranges from 2 
to 10, representing the sum of the two most common patterns of tumour growth found, with individual 
grades from 1 to 5. The Gleason Score of a pattern is only valid if that pattern occupies more than 5% 






 1.2.5 Pathogenesis 
 
Most cases of prostate cancer seem to be sporadic, with various molecular pathways involved in the 
different stages of pathogenesis. In those pathways are included tumour suppressor genes, such as p53, 
PTEN, p27, NKX3.1, as well as oncogenes like c-MYC, Bcl-2, PSCA, CYP17, among others (Mazaris 
and Tsiotras, 2013). 
 
Even though PCa appears mostly in aged men, it is thought that it usually develops throughout many 
years, with PIN being the most likely precursor entity that eventually transitions into the invasive PCa 
(DeMarzo et al., 2003). PIN exhibits cell modifications that mirror those of cancer, either being cellular 
proliferation, or other genotypic and phenotypic abnormalities that balance the scale between normal 
epithelium and cancer. It should be noted though that not every patient with PIN will develop an 
invasive disease. What makes the balance shift in favour of PCa insurgence are the molecular 
mechanisms related to oncogenes/tumour suppressor genes, microenvironment, and the androgen 
receptor (AR), which is thought to play a central role throughout the entire process of PCa (Logothetis 
et al., 2013). 
 
 1.2.6 Androgen Receptor Signalling 
 
Androgen receptor signalling is crucial for both normal prostate function and growth and 
differentiation of prostate cancer cells. The human AR gene is located on chromosome X (Xq11.2-
q12) and has 8 known exons, being around 180kb long. It codes for a protein of around 110kDa that 
has 3 major functional domains: a transcription regulatory region in the N-terminal domain (NTD), 
encoded by exon 1 and representing 60% of the protein; a DNA-binding domain (DBD), encoded by 
exons 2 and 3, which contain 2 zinc finger motifs responsible for determining the DNA sequences 
recognized by the receptors; and a C-terminal ligand-binding domain (LBD), encoded by exons 4 to 8, 
where androgen binding regulates the transcriptional activity of the receptor .  
Like other nuclear receptors, AR binds sequence-specific promoter elements on target genes and 
upregulates gene expression, functioning as a steroid-hormone activated transcription factor. The two 
major ligands are testosterone and DHT. The first is produced in testicular Leydig cells and converted 
to the latter by 5a-reductases, with a 10 times higher binding affinity. When absent, AR is sequestered 
by heat-shock proteins HSP-70 and HSP-90 in the cytoplasm, protecting it from degradation. When a 
ligand binds to the AR, several serine residues are phosphorylated due to the recruited protein kinases, 
protecting it from proteolytic degradation and dissociating the receptor from the accessory heat shock 
proteins. This leads to its dimerization and translocation into the nucleus, where it stimulates the 
transcription of androgen responsive genes, as illustrated in Figure 5 (Velcheti et al., 2008). 
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 Figure 5. AR mode of action schematics. Conversion of testosterone to DHT by 5a reductase; binding of DHT to AR leads to its 
dissociation from HSPs, causing dimerization and translocation into the nucleus, where it binds to specific DNA sequences, or 
androgen response elements (AREs); series of co-activators are recruited which ultimately leads to cell proliferation, differenciation 
and survival. Taken from Velcheti, V., Karnik, S., Bardot, S. & Prakash, O. 2008. Pathogenesis of Prostate Cancer, Lessons from 























 1.2.7 Treatment, mCRPC, and Resistance to Therapy 
 
Prostate cancer usually has a long latency period, ranging from several months to several years, with 
patients having a higher life expectancy when compared to other types of cancer. However, as the 
disease progresses to a more advanced stage and becomes metastatic (mPC), resistance to hormone 
deprivation therapy rapidly follows which is manifested as castration resistant prostate cancer (CRPC), 
eventually leading to the death of the patient.  
 
This long latency of the disease issues a different approach to treatment, based on low and high risk 
prostate cancer. For low risk prostate cancer, which by definition is characterized by PSA values lower 
than 10ng/mL and a Gleason Score of 6 or less (Klotz and Emberton, 2014), the standard practice is 
active surveillance through serial biopsies and PSA level assessments. When treatment is required, 
either due to molecular alterations of the tumour that suggest disease progression, or miss-diagnosis of 
a higher grade tumour, prostatectomy and radiotherapy are usually employed. For high risk prostate 
cancer there is no agreed definition (Chang et al., 2014), but it is usually standardized for PSA levels 
higher than 20ng/mL and Gleason Scores between 8 and 10. The purpose of treatment is to confine the 




For localized prostate cancer treatment options include prostatectomy, radiation therapy and androgen-
deprivation therapy (ADT), usually in a combined fashion. When the disease spreads and is no longer 
localized, which happens primarily to the bones but also to the lymph nodes and other sites, such as 
visceral metastasis, androgen ablation is still ensued. This is done in order to reduce the production of 
androgens by the testis, and the procedures are either orchiectomy, the use of LHRH analogues and 
antagonists, or androgen blockade, which is a combination of one of the previous two options coupled 
with an antiandrogen (i.e. finasteride). However, after an initial response which can differ between 
patients, the disease eventually progresses despite castration levels of testosterone in circulation, and 
the patient enters a new stage of the disease termed castration resistant prostate cancer, which has an 
average overall survival of 1.5 years, depending on the extent of metastasis. 
 
Men with mCRPC can continue to receive radiotherapy and other second line hormonal therapies, but 
with these having more of a palliative role, while chemotherapy becomes the standard form of 
treatment. For this matter, Docetaxel is the gold standard as first line chemotherapy. It binds and 
stabilizes β-tubulin, preventing its disassembly from the microtubule network, which in turn leads to 
cell death by mitotic catastrophe, since it stabilizes the mitotic spindle during the G2-M phase, causing 
cell cycle arrest. Another mode of action relies on lowering the apoptotic threshold by inhibiting Bcl-2 
and other anti-apoptotic family members, which allow stressed cells to undergo apoptosis (Kavallaris, 
2010). Recently, the STAMPEDE study suggested that Docetaxel should be considered not only for 
men with mCRPC, but also for men with high risk and non-metastatic disease (Prostate Cancer: 
Summary from ASCO 2015) 
 
Nevertheless, this stage of the disease is no longer termed as androgen independent, as it previously 
used to be, even though androgen ablation therapy is non-responsive, since AR signalling remains 
active as a main inducer of cancer progression. Possible explanations reside on compensatory 
mechanisms, including AR gene amplification, incomplete interruption of the ligand-dependant AR 
activation, aberrant AR co-regulator activity, AR mutations, AR and growth factors cross-talk 











 Figure 6. Schematic representation of possible mechanisms of resistance to 
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Based on these findings, novel chemotherapeutical agents have been developed and carefully 
evaluated in clinical trials, with the most commonly used AR-axis-targeted (ARAT) therapies for the 
treatment of mCRPC being Abiraterone Acetate (AA) and Enzalutamide (Enza). AA is a CYP17A1 
inhibitor, inhibiting both 17α-hyd oxylas d 17,20-lyase activities, therefore blocking androgen 
synthesis in the testes, adrenal glands and tumour microenvironment (Yin and Hu, 2014). Besides its use 
in mCRPC treatment, studies point to its potential in chemotherapy-naive patients in earlier stages of 
the disease, and also as adjuvant therapy for mCRPC (Hoy, 2013). Enza has a broader spectrum of 
action, affecting not only the interaction of the AR with its co-regulators, but also chromatin binding 
and nuclear translocation of the receptor. Studies suggest beneficial effects not only in chemotherapy-
naive mCRPC patients, but also in patients who previously failed chemotherapy (Beer et al., 2014). 
Other compounds that are not ARAT specific also exist, namely cabazitaxel, sipuleucel-T and 
Radium-223, with the first one being used for Docetaxel resistant patients, the second as an 
immunotherapeutic age t, and the third for skeletal metastasis (Chi et al., 2015). 
 
Nonetheless, most patients eventually exhibit tumour progression after treatment. This resistance to 
chemotherapy can involve intrinsic mechanisms to the tumour biology, or more generic mechanisms 
of drug resistance. For the generic ones, it can be the case of impaired drug distribution, survival 
driven by the tumour microenvironment, and/or overexpression of multi-drug resistant proteins, such 
as the ones coded by MDR1 and MDR2 - ATP-binding cassette (ABC) transporters. These could be 
responsible for excreting Docetaxel to the extracellular fluid, therefore decreasing the intracellular and 
11 
 
lethal concentrations of this drug (Seruga et al., 2011). In terms of inherent mechanisms to mCRPC 
resistance, some examples are AR gene amplification, mutation and/or overexpression of the AR 
receptor, overexpression of AR coactivators, aberrant kinase pathway activation, and expression of 
AR splice variants. These splice variants of the AR lack the ligand-binding domain, and though not 
capable of binding DHT or other androgens, they remain constitutively active and are able to promote 
or activate target genes (Chi et al., 2015). 
  
 1.2.8 Proposing a New Molecular Classification for PCa 
 
The course of treatment varies from patient to patient, and the current clinical model for prostate 
cancer groups patients by similar prognosis, for example: if there is a response to ADT, if the patient 
has developed metastasis and where, if the patient is under chemotherapy or not. This is done based on 
morphologic criteria such as the Gleason Score, and doesn't consider that the stage of cancer 
progression will determine if a therapeutically agent is effective or not.  
 
To overcome this limitation, Logothetis et al. proposed a new classification system where molecular 
markers define a specific stage of progression in order to guide therapy selection, independent of the 
tumour stage. This would incorporate the 3 molecular mechanisms that most commonly drive prostate 
cancer progression: AR, oncogenes/tumour suppressor genes, and tumour/bone microenvironment 
(Vogelstein and Kinzler, 2004).  
 
In this alternative model, illustrated in Figure 7, tumour progression is grouped in three categories: 
endocrine-driven, microenvironment-dependent, and tumour cell-autonomous. For the first category, 
treatment would be based on inhibiting DHT formation through the use of ADT. Disease progression 
would lead to a transition from an endocrine, dependent on gonadal hormones, to a paracrine phase, 
dependent on microenvironment factors, which alerts for the potential lethal progression of the cancer. 
Thereafter the patient would be in a stage the authors coined "progressive spiral", in which the 3 
"drivers" of PCa would act synergistically, leading to a tumour adaptation over time, with the tumour 
altering the microenvironment and vice-versa. In the last stage of the disease, where there is no 
positive therapeutic effect, cancer cells would exit these spiral loops and become tumour cell-
autonomous, characteristic of a big increase in tumour mass and in which cells do not secrete PSA or 
express AR. Nonetheless, this does not mean they are independent of AR signalling (Logothetis et al., 
2013). 
 
The authors proposed that the spiral turns in the paracrine phase and its inherent molecular 
mechanisms can be identified based on response to therapy. Each turn could be defined by one or 
more predictive biomarkers, and when it would reach the next turn of the progression spiral it would 
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 Figure 7. Illustrative figure of a new model of classification for PCa. Transition between the endocrine-driven phase (DHT 
dependent), the microenvironment-dependent phase ("progressive spiral"), and the tumour cell-autonomous phase. Taken from 
Logothetis, C. J., Gallick, G. E., Maity, S. N., Kim, J., Aparicio, A., Efstathiou, E. & Lin, S. H. 2013. Molecular classification of 
prostate cancer progression: foundation for marker-driven treatment of prostate cancer. Cancer Discov 3: 849-61. 
 
 








 1.2.9 Biomarkers 
 
Biomarkers can be of different nature, including proteins, RNAs such as mRNAs or miRNAs, DNA, 
or even other factors or signatures of combined nature (Ploussard and de la Taille, 2010) 
 
PSA as a biomarker really made an impact in prostate cancer management, but its use remains 
controversial to some extent, since activities that are unrelated to the presence of cancer can induce the 
expression and secretion of this molecule (Duijvesz et al., 2011). This makes it so that an invasive 
procedure such as a prostate biopsy still remains the only diagnostic tool available, highlighting the 
need for new biomarkers that improve early PCa detection. Not only this, but following in on the 
previous subchapter (Proposing a New Molecular Classification for PCa), it is of crucial importance to 
identify biomarkers that are prognostic and/or predictive of response to therapy, thus allowing for 
changes in the course of treatment as early as possible. Even though none of the following have been 
validated as predictive biomarkers, factors such as duration of response to ADT, Gleason Score, PSA 
response, androgen levels at baseline, chromogranin A, and the fusion protein TMPRSS2-ERG are 
good examples. 
 
PCa biomarker discovery has focused on protein expression changes and aberrations in the AR gene. 
Other potential candidates are nuclear AR, cytoplasmic CYP17 expression, AR amplifications, and 
AR copy number, with some of these being associated with poor response to ARAT agents such as 
AA and Enza (Chi et al., 2015). 
 
More recent studies have focused on other entities as source of biomarkers. One example entails 
circulating tumour cells (CTCs). In patients with mCRPC, the number of CTCs can be a marker of 
response to therapy, while the baseline number of these circulating cells could represent a prognostic 
marker of overall survival (Nakazawa et al., 2015). Moreover, Antonarakis et al. proposed that the 
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presence of a specific splice variant of the androgen receptor in CTCs, the AR-V7, is not only 
associated with resistance to AA and Enza in patients with mCRPC, but can also provide information 
on tumour status and stage of disease progression (Antonarakis et al., 2014). 
 
On a similar fashion to CTCs, another possible source of biomarkers relies on extracellular vesicles, 
and more specifically, exosomes. Cancer cells have different genotypic and phenotypic profiles 
compared to normal cells, and since these vesicles share their content with the vesicle-producing cells, 
exosomes derived from cancer cells would share similar molecular profiles and could, therefore, carry 
the same and/or different markers. The even higher suitability of these vesicles as biomarkers resides 
on the fact that they are produced by all cells (studied in this regard thus far) and can be isolated from 
circulating fluids, such as blood and urine, without the need of more invasive procedures (Øverbye et 
al., 2015).  
 
Despite the promising candidates, further studies are required in order to validate the correlation of all 



























Communication between cells is a crucial hallmark for the survival of multicellular organisms. If, for 
example, we look at the communication that occurs between tumour and stromal cells, or even 
between tumour and more distant cells, this is accomplished by: cell-cell interactions, such as tight-
junctions; paracrine mechanisms, including growth factors, proteases and chemokines; and also by 
extracellular vesicles (EVs). EVs are secreted by cells both under physiological and pathological 
conditions, such as cancer, with exosomes being the most studied type of EV (Kharaziha et al., 2012). 
 
Exosomes were first discovered in 1987 by Johnstone et al., under the observation that sheep 
reticulocytes under maturation secreted exosomes in order to excrete the transferrin receptor (Johnstone 
et al., 1987). These and other EVs were initially regarded as having no biological significance other 
than excreting debris and unwanted material from the cell, until Raposo et al. demonstrated that EVs 
could indeed hold biological significance, in this case by stimulating adaptive immune responses 
(Raposo et al., 1996). 
 
Other types of EVs include microvesicles, apoptotic bodies, and others, which often have overlapping 
nomenclature and/or definition, not to mention that different reports tend to have different definitions 
of the same EVs. Apoptotic bodies are the overall biggest, with sizes ranging from 500nm to 2000nm, 
and they are characteristic of cells undergoing apoptosis, containing fragments of the nuclear 
components and cellular organelles. Microvesicles are smaller in size when compared to apoptotic 
bodies, but still show sizes from 50 to 1000nm, while floating at a high density on a linear sucrose 
gradient (Mathivanan et al., 2010).  
 
Exosomes are the smallest of the three and have a more confined size range, between 50 and 150nm. 
They are homogenous in shape, with a characteristic "cup" format when visualized by electron 












 Figure 8. Illustrative figure of molecular 
constitutents of exosomes. Taken from Kharaziha, P., 
Ceder, S., Li, Q. & Panaretakis, T. 2012. Tumour cell-
derived exosomes: a message in a bottle. Biochim 
Biophys Acta 1826: 103-11. 
 
 
 1.3.1 Composition 
 
The underlying mechanism of exosome function is not fully 
understood, but their complexity can easily be observed just by 
looking at their molecular composition. Their content, 
illustrated here in Figure 8, usually reflects that of the 
originating cells. They contain a variety of proteins and nucleic 
acids (DNA, mRNA, miRNA, lncRNA, rRNA and mtDNA), 
and are usually enriched in specific proteins, such as the 
tetraspanins CD63, CD81, CD82, CD9, among others (Gajos-
Michniewicz et al., 2014). Some of these proteins are involved in 
multivesicular body formation, such as Alix, TSG101, clathrins, 
while other proteins are of endosomal origin, such as Annexins, 
Rab GTPases and SNAREs. Another interesting characteristic is that exosome´s lipid bilayer also 
differs from the originating cells, conferring added rigidity and stabilizing these vesicles in biological 
fluids. The differences are in the enrichment of lipid rafts, phospholipids, diglycerides, 
glycerophospholipids, phosphatidylinositol, sphingolipids, and others (Kharaziha et al., 2012). Some of 
these molecular entities serve as exosomal markers. 
 
 1.3.2 Biogenesis and Uptake 
 
The two main classes of EVs that take part in cell to cell communication are microvesicles and 
exosomes. While microvesicles are produced through budding of the plasma membrane, exosomes are 
originated from the endolysosomal pathway (Andaloussi et al., 2013). First, there is formation of early 
endosomes by fusion of endocytic vesicles with the plasma membrane. Then there is a maturation 
step, in which multivesicular bodies (MVBs) are formed after fusion of the early endosome with 
intraluminal vesicles (ILVs). The last step is the fusion of these MVBs with the plasma membrane, 
which results in the release of ILVs to the extracellular compartment, now termed exosomes (Babst, 
2005). This is facilitated by the endosomal sorting complex required for transport, or ESCRT, and 
these complexes are the initiators of the membrane budding that forms ILV's, by recognizing and 
organizing ubiquitinated proteins within the late endosomes (Wollert and Hurley, 2010). The process of 
targeting the mature MVBs to the cell membrane is done by various Rab-GTPases, like Rab27a and b, 
fusing with the cellular membrane to release exosomes to the extracellular space (Ludwig and Giebel, 
2012). An ESCRT-independent mechanism of exosome biogenesis, based on lipid rafts, ceramide and 




Flowing in the other direction we have exosome uptake by recipient cells, which can be located at 
distant sites or in the vicinity of the secreting cells. This can be done by the following mechanisms: 
fusion of the cell membrane with the exosomes, leading to a direct release of the exosomal content in 
the cytoplasm; receptor proteins that facilitate exosomal binding with the target cells; and endocytosis 
(Gajos-Michniewicz et al., 2014). 
 
 1.3.3 Isolation and Characterization 
 
In order to be able to perform exosomal studies it is crucial to employ proper and standardized 
exosome isolation techniques, with the goal being the isolation of exosomes from cell culture 
supernatants and/or body fluids (i.e. urine, blood). The gold standard in terms of isolation is 
differential ultracentrifugation. The tricky part of working with exosomes resides on the contamination 
of the exosome preparations by other EVs (i.e. microvesicles), since this is a size exclusion-based 
procedure, and the even though exosomes have very specific size-ranges, other EVs can have an 
overlapping spectrum. One way of purifying an exosome sample is to run it through a sucrose density 
gradient, based on the principle that vesicles other than exosomes float on different densities. The size 
distribution of your exosome isolation and particle count can be determined by nanoparticle tracking 
analysis (NTA). To complement these methods, imaging techniques such as transmission electron 
microscopy (TEM) are used in order to visualize and determine size and morphology of the isolated 
exosomes. In addition to these physical characteristics, they express exosomal markers such as the 
tetraspanins CD9, CD63, CD81, the tumour susceptibility gene 101 (Tsg101), Rab5, and Alix, which 
are routinely used for exosome characterization. The validity of these markers on an exosome isolation 
can be assessed by western blot, immunophenotyping using exosomes bound on beads, or by sucrose 
gradient fractions (Thery et al., 2006).  
 
In recent years, efforts have been made to adapt already existing techniques to exosome isolation and 
characterization, such as microfluidic devices, flow cytometry based techniques, among others, but the 
aforementioned procedures remain the gold standard. It is important to mention though that the reason 
for this not only resides on the technical difficulties of working with very small particles, but also in 
the importance of having globally used techniques from which results stemming from different studies 
can be compared and extrapolated (Thery et al., 2006). 
  
 1.3.4 Potential Functional Activities 
 
Exosomes are crucial for cell communication, as they are in charge of lipid trafficking and transport of 
other bioactive molecules between cells. These vesicles have been identified in body fluids from 
healthy patients, hinting for their role in normal body's physiology (Vlassov et al., 2012). In contrast, it 
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has also been observed that body fluids from cancer patients showed an increase in exosome levels 
when compared to healthy controls (Azmi et al., 2013). These observations seem to indicate that 
exosomes might have different functions depending on the cells they originate from. On a 
physiological role, exosomes not only transfer DNA, RNA and proteins to other cells, but also 
modulate immune response and present antigens to immune cells (Andaloussi et al., 2013). But 
exosomes also seem to play an important role in the cancer setting: they can promote metastasis; alter 
the phenotypic characteristics of recipient cells; differentiate normal fibroblasts to myofibroblasts in a 
pro-tumour growth fashion; transfer resistance to chemotherapy; and stimulate cell migration and 
invasion (Costa-Silva et al., 2015). 
 
A revolutionary finding was unravelled this year, showing that exosomes might not only be 
responsible for the transport of bioactive molecules, but might also have the potential to synthesize or 
at least process those same molecules. In this regard, Melo et al. showed that exosomes have the 
ability to perform cell-independent miRNA biogenesis and therefore promote tumorigenesis as an 
individual entity (Melo et al., 2014). 
 
 1.3.5 Clinical Benefits as a Source of Biomarkers 
 
The possibility of malignancy or disease detection by non-invasive means, coupled to the concept that 
exosomes represent molecular fingerprints of the secreting cells, puts these vesicles in the focus of 
biomarker research (Duijvesz et al., 2011)  
 
Following this idea, several studies incorporating proteomics and transcriptomics approaches have 
been applied on exosome research (Dijkstra et al., 2014, Duijvesz et al., 2013, Øverbye et al., 2015). 
 
One example that revolutionized the field, and that took any possible doubt out of the idea of using 
exosomes as biomarkers, was the study performed by Melo et al. It shows that Glypican-1, a 
membrane-anchored protein that is overexpressed in breast and pancreatic cancer, can be used as a 
biomarker that distinguishes cancer exosomes from normal exosomes. Moreover, it also suggests that 
Glypican-1 positive exosomes may serve as screening and diagnostic tool for detection of early stages 
of pancreatic cancer, with absolute specificity and sensitivity (Melo et al., 2015). 
 
This remains to be validated on a bigger cohort of patients, and in other types of cancer, but the 
potential of using exosomes either as biomarkers or as a source of biomarkers is there. However, there 




1.3 AIM OF THE STUDY 
 
The aim of this project is to study prostate cancer-derived exosomes, with special focus on resistance 
to therapy.  
 
For that purpose, we developed cell lines that are resistant to specific chemotherapeutic agents used in 
the treatment of mCRPC. This was done on a progressive fashion, starting with the golden standard of 
CRPC therapy, Docetaxel (Taxotere) and with a recently introduced anti-cancer agent, Abiraterone 
Acetate (Ryan et al., 2013). The cell lines in question are LNCaP, a non-metastatic prostate cancer cell 
line, mimicking initial stages of the disease, and DU145, highly metastatic, representing an advanced 
stage of prostate cancer. The cell line model used was: first, DU145 and DUR (resistant to Docetaxel); 
second, DU145, DUAAR (resistant to Abiraterone Acetate), LNCaP, and LNAAR (resistant to 
Abiraterone Acetate). 
 
The objective is to isolate exosomes from these cell lines, proceed to their characterization, and 
perform a comparative proteomics analysis with the ultimate goal of identifying predictive biomarkers 





























2. MATERIALS AND METHODS 
Antibodies and reagents 
  
The primary antibodies used in this study were: Rab 5, CD81, CD82, Alix, Emmprin and Caveolin-1, 
from Cell Signaling Technology; TSG101, CD9, CD82 and PACSIN2, from Abcam; MDR-1 and 
MDR-3, from GeneTex; AIF, CD9, CD63, CD81, Endophilin A2, PACSIN2 and AR (N-20), from 
Santa Cruz Biotechnology; CYP17A1, from Novus Biologicals. The HRP-conjugated secondary 
antibodies, anti-mouse and anti-rabbit, were obtained from Cell Signaling Technology. 
  
The chemotherapeutical agents Docetaxel and Abiraterone Acetate were obtained from Seleck 
Chemicals. 
  
Cell lines and culture conditions 
  




) is derived from a human prostate 




) is also a human prostate cancer 
cell line, established from a metastatic deposit in a lymph node.  
  
The resistant cell lines were generated by growing the cells with increased concentrations of the 
respective drug for several weeks. DUR cell line was treated with Docetaxel until growth was 
observed at a final concentration of 500 ng/mL. DUAAR and LNAAR cell lines were treated with 
Abiraterone Acetate until growth was observed at final concentrations of 30 µM and 20 µM, 
respectively. All cell lines were cultured in 175 cm
2
 flasks using RPMI 1640 (Hyclone), supplemented 
with 10% Fetal Bovine Serum (Hyclone), 2mM L-Glutamine, and 50 µg/mL of Penicillin and 
Streptomycin (GIBCO). For exosome isolation cells were cultured for 48 hours in vesicle depleted 
medium, as described below. 
  
Conditioned Media and Exosome Isolation 
  
Exosomes were isolated from cells cultured in conditioned medium. In order to deplete vesicles from 
medium, RPMI 1640 supplemented with 30% Fetal Bovine Serum (FBS) was ultracentrifuged 
overnight at 120,000g, 4ºC. The pellet was discarded and the supernatant was then filtered through a 
0.22 μm vacuum system, diluted with RPMI 1640 to reach a 10% final concentration of FBS, and 




Cells were cultured in conditioned media in multilayer flasks (Millicell® HY, from Millipore) until 
they reached 70 to 80% confluency (48-72h). Supernatants were then collected, centrifuged at 1000g 
at room temperature and filtered through a 0,22 μm vacuum system. Supernatants were then frozen at -
20
o
C. Prior to exosome isolation the supernatants were thawed at 4
o
C and centrifuged at 120,000g for 
2h at 4ºC. The supernatants were discarded and the pellets were washed in a phosphate buffered 
solution (PBS) and ultracentrifuged again for 120,000g for 2h at 4ºC. The resulting exosome pellet 
was then ressuspended in 1x PBS (100 µL to 500 µL) and stored at -80ºC. Exosomes used for Western 




Cells and exosomes were lysed in a modified RIPA buffer. This buffer contains 50mM Tris, 150mM 
NaCl, 1mM EDTA, 1% IGEPAL, 1% glycerol (pH adjusted to 7.4), with added PhosSTOP and 
Phosphatase Inhibitor Cocktails (Roche), Complete Protease Inhibitor Cocktail (Roche), 100mM 
vanadate (Life technologies), and 1mM dithiothreitol (DTT) (Sigma Aldrich). For exosomes 
ressuspended in PBS, a 4 times concentrated RIPA buffer was used, 
  
After lysis of cells and/or exosomes for 30 minutes on ice with 1x or 4x RIPA buffer, respectively, 
protein concentration was determined using a Bradford assay (Bio-Rad). Equal amounts of protein 
(15μg unless stated otherwise) were denatured for 5 minutes at 90ºC, and resolved by SDS-PAGE 
(sodium dodecyl sulphate - polyacrylamide gel electrophoresis) in 10 or 12% Bis-Tris gels (Life 
Technologies), according to manufactures instructions. Proteins were then transferred to PVDF 
membranes (Perkin Elmer) and blocked in 5% (w/v) non-fat dry milk in 1x TBST, for 1hour in room 
temperature. The blots were then probed with specific primary antibodies (1:1000 dilutions unless 
stated otherwise), and then with horseradish peroxidase-conjugated secondary antibodies (1:2000). 
The bands were detected by chemiluminescence using ECL, ECL+, ECL pro or ECL ultra 
(PerkinElmer) after exposure on X-ray films (CL-exposure Film, Thermo Scientific). 
  
Sucrose density gradient 
 
We used a 0,2M to 2M sucrose gradient; we added the exosomes on its surface and ultracentrifuged at 
120,000g, for 20 hours at 4ºC. The fractions were collected (10 fractions / 1ml each), ressuspended in 







Nanoparticle Tracking Analysis (NTA) 
  
For the secretion study, NS500 (Nanosight Limited, London, UK) was used, equipped with an 8 mega 
pixel camera (Andor Technology, Tokyo, Japan) and a 405 nm laser, in order to measure the size and 
determine concentration of exosomes. NTA v2.3.0.17 software (NanoSight Limited) was used for both 
data acquisition and analysis. Three samples from each exosome type were measured and their 
average was calculated. The duration of each video was 5 minutes. During the analysis procedure the 
camera level was 14 and the detection threshold was 15. 
  
Electron Microscopy – negative staining 
  
3μl of the sample were added to a grid with carbon supporting film for 5 minutes and then the grid was 
rinsed by adding 5μl dH2O for 10seconds, soaked off and stained with 1% uranyl Acetate in water for 
10 seconds and air-dried. A Tecnai 12 Spirit Bio TWIN transmission electron microscope (FEI 
Company, Eindhoven, Netherlands) at 100kV was used for the examination of the samples. A Veleta 





Protein extraction and digestion, liquid chromatography tandem mass spectrometry and data analysis 
were done in collaboration by Dorothea Rutishauser from Roman Zubarev’s group (Department of 
Medical Biochemistry and Biophysics, Karolinska Institutet, Sweden), according to the protocol 




























This section will be divided in two parts, since this study was done on a sequential fashion, with the 
first part addressing biomarkers for resistance to Docetaxel, and the second part for resistance to 
Abiraterone Acetate. 
 
 3.1. Exosomes originated from Docetaxel sensitive (DUS) and resistant (DUR cells) 
DU145 cells  
 
We have generated DU145 cells stably resistant to 500 ng/mL of Docetaxel (DUR cells). Figure 3.1A 
shows an Annexin V/PI staining comparing cell death profiles between DUS and DUR cells, after 24h 
and 48h treatment with 50 ng/mL Docetaxel. Results indicate that DUR cells do not undergo cell death 
after treatment, while there is a more than double percentage increase in terms of cell death in the 
DUS cells, both at 24h and 48h of treatment. 
 
We have isolated exosomes from the supernatants of these 2 cells lines, DUS and DUR, and proceeded 
to their characterization. 
 
 3.1.1. Exosome Characterization 
 
Transmission Electron Microscopy images, presented in Figure 3.1B, show that exosomes isolated 
from both DUS and DUR cell lines have an homogenous structure, with a median diameter of about 
100 nm. Nanoparticle tracking analysis (NTA) provided a size distribution profile plus a relative 
concentration of the isolated exosomes, as shown in Figure 3.2C. Regarding particle size, most of the 
isolated vesicles are around 100 nm, with the DUS exosomes being slightly bigger than the DUR 
exosomes. Besides, NTA particle concentration values indicate that DUR cells secrete more exosomes 
than DUS cells. 
 
Next we evaluated the presence of generic exosome markers by western blot analysis, represented in 
Figure 3.1D. Both DUS exosomes and DUR exosomes seem to be enriched in TSG101, CD9 and Alix, 
when compared to the cells that secrete those same exosomes. From the evaluated markers, only CD82 
seems enriched specifically in DUR exosomes and not in DUS exosomes. 
 
Further characterization involved loading exosomes into a linear sucrose gradients to evaluate their 
distribution based on their density. This was done both by NTA and western blotting. Exosomes 
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typically float at densities between 1.13 and 1.19 g/mL (Thery et al., 2006), and Figure 3.2A not only 
hints at a relatively good yield, since most particles isolated float at those densities (1.12 to 1.19 g/mL, 
seen by NTA), but also supports the hypothesis proposed in Figure 3.1C, that DUR cells secrete more 
exosomes than DUS cells. These sucrose gradient fractions were then analysed by western blot for the 
presence of classical exosomal markers, as seen in Figure 3.2B, C. Both DUS and DUR exosomes 
show enrichment in TSG101, Rab5 and CD9 in the characteristic exosome fractions. Interestingly, 
DUS exosomes present a broader density distribution, between 1.12 and 1.19 g/mL, when compared to 
DUR exosomes, between 1.13 and 1.18 g/mL. 
 
 3.1.2. Proteomics Profiling of exosomes 
 
Proteomics analysis of DUS and DUR exosomes identified 914 proteins (criteria of at least 1 peptide 
with an FDR ≤ 1%) by nLC-MS/MS (Kharaziha et al., 2015). As illustrated by the Venn diagram shown 
in Figure 3.3A, of these 914 proteins, 146 were unique for DUR exosomes, 417 were unique for DUS 
exosomes, and 351 were common for both. 
 
The next step was to perform bioinformatics analysis, and using the Ingenuity software, we identified 
the top 12 pathways in which these proteins are involved, as shown in Figure 3.3B. With no major 
differences between DUS and DUR exosomes, 3 pathways were found to have slight differences - 
epithelial adherence junctions, remodelling of adherence junctions, and eIF2 signalling. We also did 
additional classification of these proteins, using Gene Ontology (GO) annotations from PANTHER™, 
in regards to biological processes, molecular functions, cellular component, and protein class, as 
shown in Figure 3.3C. DUR exosomal proteins seem to be more involved in processes such as 
metabolic activity and nucleic acid binding, while DUS exosomal proteins were more related to 
processes like biological adhesion, cellular organization, enzyme regulation and receptor activity. 
 
Based on unsupervised hierarchical clustering of the total number of proteins, we then selected the top 
100 proteins in terms of abundance in DUS and DUR exosomes. These top 100 proteins are 
represented in the form of a heat map in Figure 3.4A, which shows differences between DUS and 
DUR cells, between DUS and DUR exosomes, and between cells and exosomes of the same cell line.  
 
 3.1.3. Validation 
 
We then selected the proteins that show the biggest difference in abundance between DUS and DUR 
exosomes for validation by western blotting, as shown in Figure 3.4B. The most enriched protein 
found in DUR exosomes compared to DUS exosomes was Endophilin A2, with MDR1 being another 
example. Other proteins evaluated were MDR3, PABP4, PACSIN2, CYP17A1, Emmprin and 
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Caveolin-1. Interestingly, MDR1 was enriched in DUR exosomes and found absent in DUS exosomes, 
with other proteins also showing differences between these two samples. TSG101 and Rab5 were used 
as exosomal markers, while AIF was used for quality control of the exosomal isolation. To further 
assess the validity of these results, we probed for MDR1 and MDR3 after loading DUS and DUR 
exosomes on a sucrose gradient, using TSG101 as an exosomal marker. 
 
 3.2. Exosomes originated from Abiraterone Acetate sensitive and resistant DU145 and 
LNCaP cells 
 
We have generated DU145 cells and LNCaP cells resistant to 30 and 20µM of Abiraterone Acetate 
(AA), respectively, DUAAR and LNAAR cells. Figure 3.5 shows cell death profiles of DU145-
DUAAR and LNCaP-LNAAR cells after 48h treatment with 30 and 20µM of AA, respectively. 
Results indicate that the DUAAR cells have acquired some resistance to AA. LNCaP cells did not 
undergo cell death in response to AA but even in this setting there was a small decrease in the amount 
of dead cells in AA treated LNAAR cells. Further evidence for the acquisition of resistance to AA 
come from the iCELLigence studies (ACEA Biosciences). There is a considerable difference in the 
cell proliferation of LNAAR cells showing higher proliferation rates compared to LNCaP cells (Figure 
3.6). DUAAR cells also show increased proliferation compared to DU145 cells, but to a lesser extent. 
Due to limitations in the usage of the iCELLigence equipment data we have not quantified the 
statistical significance of these data but these experiments are planned and ongoing. . 
 
We have isolated exosomes from the supernatants of these 4 cells lines, DU14, DUAAR, LNCaP, and 
LNAAR, and proceeded to their characterization. 
 
 3.2.1. Exosome Characterization 
 
Transmission Electron Microscopy (TEM) images, show that exosomes isolated from DUAAR and 
LNAAR cell lines present the characteristic exosomal structure (Figure 3.7A). The size measured in 
the TEM, indicate that these vesicles have diameters of approximately 100nm. Nanoparticle tracking 
analysis (NTA) provided a size distribution profile and a relative concentration of the isolated 
exosomes, as shown in Figure 3.7B. All cell lines show a typical size distribution profile of isolated 
exosomes, with the LNCaP and LNAAR exosome populations being represented mostly by vesicles 
around 100 nm, while the DU145 and DUAAR exosome populations were mostly represented by 
vesicles slightly bigger, around 120 nm in diameter. An interesting finding is that both DUAAR and 
LNAAR cells seem to secrete more exosomes than their sensitive counterparts. Besides, DUAAR cells 




Next, we evaluated the presence of generic EV markers by western blot analysis, represented in Figure 
3.8A. All exosome populations seem to be highly enriched in both CD9 and CD81 when compared to 
the originating cells. From the evaluated markers, other observations that might be of value are the 
higher abundance of TSG101 and Alix in LNAAR exosomes when compared to all other samples.  
Rab5 was in lower abundance in both LNCaP and LNAAR exosomes when compared to all other 
samples, and also demonstrated different size and/or different sedimentation profile that Alix presents 
in whole cell lysates compared to exosomes.  
 
Further characterization involved loading exosomes into linear sucrose gradients to evaluate the 
presence of exosome markers in the characteristic exosome densities, done by western blotting. 
Exosomes typically float at densities between 1.13 and 1.19 g/mL (Thery et al., 2006), and Figure 3.8B 
shows a western blot analysis of the DUAAR and LNAAR exosome sucrose fractions. This result 
points to a relatively good exosome yield in terms of purity, since the bands for the evaluated markers, 
Alix and CD9, show enrichment or higher abundance in the characteristic densities where exosomes 
tend to float (1.12 to 1.19 g/mL). Another observation is that DUAAR exosomes have a broader 
distribution when compared to LNAAR exosomes.  
 
 3.2.2. Proteomics Profiling of exosomes 
 
Proteomics analysis of DU145, DUAAR, LNCaP and LNAAR exosomes identified several proteins 
(criteria of at least 1 peptide with an FDR ≤ 1%) by nLC-MS/MS (data not shown).  
 
We performed bioinformatics analysis, and we classified these proteins based on Gene Ontology (GO) 
annotations (PANTHER™) in regards to biological processes, molecular functions, cellular 
component, and protein class, as shown in Figures 3.9 and 3.10. This analysis was always done in a 
comparison fashion between resistant and sensitive exosomes, so DUAAR exosomes versus DU145 
exosomes and LNAAR exosomes versus LNCaP exosomes. A list of proteins to evaluate was chosen 
based on an selected threshold value of 2. An interesting difference that can be observed is that DU145 
exosomes seem to be involved in nucleic acid binding transcription factor activity, while DUAAR 
exosomes didn't present this category. DU145 exosomal proteins also appear to relate more to 
membrane and cell components, when compared to DUAAR exosomes. Both DUAAR and LNAAR 
exosomes seem to contain more proteins involved in response to stimuli and related to extracellular 
matrix, when compared to their sensitive counterparts. LNAAR exosomal proteins are also more 
involved in processes like enzyme regulator activity and nucleic acid binding, when compared to 





 3.2.3. Validation 
 
Bioinformatics analysis and validation is still ongoing. One interesting aspect is the enrichment of the 
AR in the exosomes. The efficacy of the AA is affected by the androgen receptor (AR) status, i.e. 
expression of the wild type isoform or alternative splice variants. We evaluated, by western blot, the 
presence of the AR it in our cell lines and exosomes. The uncut western blot image is shown in Figure 
3.11, and only the LNCaP and LNAAR cells show a clear band characteristic of the full length 
androgen receptor (AR-FL) at around 110 kDa. The LNCaP and LNAAR exosomes also seem to 
present faint bands at those molecular weights, but the low intensity of the signal doesn't allow proper 
interpretation. Interestingly, while DU145 and DUAAR exosomes seem to be have an equivalent 
abundance of AR compared to the producing cells, in the LNCaP and LNAAR setting that is not 
verified, as cells show a much higher abundancy than exosomes. Other bands with varying molecular 
weights that appear throughout the different lanes, but mostly on LNCaP and LNAAR cells, could 
represent the different splice variants (SV) of the AR. On this matter, DUAAR exosomes seem to have 
higher abundance of these AR-SVs when compared to DU145 cells, and while these seem equivalent 
between LNAAR and LNCaP exosomes, the opposite effect is verified between LNCaP and LNAAR 
cells, with the latter showing less abundance. Another interesting phenomena that seems to be general 
and not only related to the AR is that, sometimes, bands that represent the same protein seem to either 
have a different running profile, or to have different molecular weights between cells and exosomes, 
which is happening in this blot, as seen by the bands in the exosomes appearing slightly in higher 













































Figure 3.1: Characterization of exosomes secreted from DUS and DUR cells, with prior cell 
death profiling of those same cells. (A) Quantitative analysis of Annexin V/PI positive DU145 and 
DUR cells after 50 ng/mL Docetaxel treatment for 24h and 48h (means ± SD, n = 3); (B) Exosomes 
isolated from DUS and DUR cells were visualized by transmission electron microscopy (bar size: 100 
nm); (C) Nanoparticle tracking analysis on an LM10 Nanosight demonstrating a mean size of 100 nm 
for DU145 Tax-Res and 120 nm for DU145 Tax-Sen exosomes. The size distribution and relative 
concentration were calculated by the Nanosight software (n = 3); (D) Western blot analysis of 10 μg 



































Figure 3.2: Comparative biochemical characterization of exosomes isolated from DU145 Tax-
Sen and DU145 Tax-Res cells. (A) Nanoparticle tracking analysis of sucrose gradient fractions with 
the indicated sucrose density. The size distribution and relative concentration were calculated by the 
Nanosight software (n = 3); (B), (C) Western blot analysis of the sucrose gradient fractions from 








Figure 3.3: Bioinformatics analysis of the DU145 Tax-Sen and DU145 Tax-Res exosomal 
proteome. (A) Venn Diagram constructed from the unique and shared proteins identified in DU145 
and DUR exosomes; (B) Ingenuity pathway analysis of the signalling cascades identified in the 
proteomics analysis; (C) Pie charts from the GO classification analysis (PANTHER 9.0) of the 
















Figure 3.4: Proteomics profiling of exosomes isolated from DU145 and DUR cells. (A) Heat map 
of the hierarchical clustering of the 100 most abundant protein identified. The values were mean-
centred and log-transformed. The relative protein abundance is colour-coded with red corresponding 
to a relatively high abundance, green to a relatively low abundance, and black indicating indifferent 
abundance values. Each exosome sample was analysed in duplicates; (B) Western blot analysis of 
10μg of DU145 and DUR exosomes, probed for the indicated proteins. Rab5 and TSG101 were used 
as exosomal markers and AIF as a quality control of the exosomal isolation (n = 2); (C) Western blot 
analysis of the sucrose gradient fractions from DU145 and DUR exosomes, probed for MDR-1/3 and 






































Figure 3.5: Cell death profiling of DU145, DUAAR, LNCaP and LNAAR cells by Annexin V/PI 
staining. (A) Quantitative analysis of Annexin V/PI positive DU145 and DUAAR cells after 30µM 
AA treatment for 48h (means ± SD, n = 3): percentage of alive cells represented in green and 
percentage of dead cells represented in grey; (B) Quantitative analysis of Annexin V/PI positive 
LNCaP and LNAAR cells after 20µM AA treatment for 48h (means ± SD, n = 3): percentage of alive 





















Figure 3.6: Cell proliferation profiling of DU145, DUAAR, LNCaP and LNAAR cells by 
iCELLigence. (A) Cell proliferation assessment of DU145 cells compared to DUAAR cells after 72h 
treatment with 30µM AA. Experiment was performed in duplicates, with DU145 cells represented in 
red and green, and DUAAR cells represented in blue and pink; (B) Cell proliferation assessment of 
LNCaP cells compared to LNAAR cells after 72h treatment with 20µM AA. Experiment was 
performed in duplicates, with LNCaP cells represented in red and green, and LNAAR cells 
represented in blue and pink;  In both (A) and (B), quantitative data could not be taken into 
consideration due to instrument limitations. The x-axis represents time (in hours) and the y-axis 





























































Figure 3.7: Characterization of exosomes secreted from DU145, DUAAR, LNCaP and LNAAR 
cells. (A) Exosomes isolated from LNCaP, LNAAR, DU145 and DUAAR cells were visualized by 
transmission electron microscopy (scale bar: 100 nm) (B) Nanoparticle tracking analysis on an LM10 
Nanosight showing: a mean size of 100 nm for LNCaP and LNAAR exosomes, and 120 nm for 
DU145 and DUAAR exosomes; that DUAAR and LNAAR cells secrete more exosomes than their 
sensitive counterparts, DU145 and LNCaP cells, respectively. The size distribution and relative 

























Figure 3.8: Characterization of exosomes secreted from DU145, DUAAR, LNCaP and LNAAR 
cells by western blot and sucrose gradients. (A) Western blot analysis of 15 μg lysates of the 
mentioned cell lines and respective exosomes, probed for the indicated proteins (n = 2). (B) Western 
blot analysis of the sucrose gradient fractions from DUAAR and LNAAR exosomes, respectively, 
probed for Alix and CD9, (n = 2). Numbers 1 to 10 represent a scale of density in g/mL: 1 represents 

































Figure 3.9: Bioinformatics analysis of the DUAAR and DU145 exosomal proteome. (A) Pie charts 
from the GO classification analysis (PANTHER 9.0) of the biological processes, molecular functions 


























Figure 3.10: Bioinformatics analysis of the LNCaP and LNAAR exosomal proteome. (A) Pie 
charts from the GO classification analysis (PANTHER 9.0) of the biological processes, molecular 
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Figure 3.11: Androgen Receptor Profiling of DU145, DUAAR, LNCaP and LNAAR cells and 
exosomes by western blotting. 15 μg of proteins from the indicated lysates were used, probed for the 


















Exosome production and release is a systematic event that, in normal physiological conditions, is 
important for the maintenance of homeostasis in living organisms. On the other hand, cancer derived 
exosomes have received attention in past years for their clinical relevance and possible influence in 
practically every hallmark of cancer. They have been shown to promote cancer progression through 
tumour immune evasion, horizontal transfer of mutant oncogenic proteins and RNAs, and also by 
modulating the tumour microenvironment (Andaloussi et al., 2013, De Toro et al., 2015). However, the 
role of exosomes in resistance to therapy remains somewhat elusive, and understanding the inherent 
mechanisms could potentially lead to the discovery of novel biomarkers that predict response to 
therapy. 
 
This is particularly important for PCa, since if the disease progresses into mCRPC, resistance to 
chemotherapy usually follows. The model used in this study is based on two prostate cancer cell lines, 
DU145 and LNCaP, and derivative cell lines from these two that were developed to become resistant 
to two drugs used clinically in mCRPC management, DUR, resistant to the gold standard Docetaxel, 
and DUAAR and LNAAR, resistant to Abiraterone Acetate. In this model, the DU145, DUR and 
DUAAR cells represent a more advanced stage of the disease (mCRPC), since they don't express the 
full length androgen receptor and have, for example, mutated p53. In contrast, LNCaP and LNAAR 
cells are highly responsive to androgens, representing an earlier stage of PCa. To assess if the cells 
were resistant or not, an Annexin V/PI staining procedure was employed. This is a cell death assay in 
which Annexin V binds to exposed phosphatidylserine, usually confined to the inner leaflet of the cells 
membrane, but exposed in the outer leaflet of the membrane when cells start undergoing apoptosis. 
Annexin V marks cells undergoing early apoptosis, and PI binds to DNA, allowing for a distinction 
between alive and dead cells in a given population. Looking at Figure 3.1A, DUR cells seem to be 
stably resistant to Docetaxel at concentrations of 50 ng/mL even after 48h of treatment. In a similar 
fashion, DUAAR and LNAAR cells were not as responsive to AA as were the parental sensitive cell 
lines. Albeit, the decrease of cell death was not as pronounced as in DUR cells. In addition the levels 
of cell death induced by AA were significantly lower than that induced by Docetaxel. Furthermore, the 
cells were growing in culture under pressure for several months, and a clear difference could be seen 
in these cells after several weeks of treatment, either in terms of morphology or in terms of growth 
rates (data not shown). This was specially true for LNCaP, since they were basically not growing 
under treatment with AA for the first several weeks, which could indicate that they were in some sort 
of cell cycle arrest, but eventually they started growing under constant treatment with AA. Figure 3.6 
clearly shows this, even though data is not quantifiable due to instrument issues: cells were treated 
with respective doses of AA after 1h of seeding (20 µM for LNCaP and LNAAR, and 30 µM for 
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DU145 and DUAAR cells), to let cells attach, and cell proliferation profiles were measured for 72h. 
LNAAR cells clearly show a difference when compared to LNCaP cells, with the two populations 
being separated after approximately 36h of treatment. Between the DUAAR and DU145 cells, this 
separation is not so noticeable, even though present. A possible explanation for the DUAAR cells is 
that, since these cells do not express the AR-FL, and with AA being an ARAT drug, when we were 
trying to develop resistant DUAAR cells, cells that were not really resistant to the drug were actually 
growing even though they were under chemical pressure. Nonetheless, the cell lines resistant to AA 
are clearly different than the regular DU145 and LNCaP cells, as seen by complementing the cell 
death assay with the cell proliferation. It is important to mention though that this claim needs further 
validation by complementing other methods to evaluate cell death and cell proliferation while looking 
at IC50 values of these cells lines to the respective drugs. 
 
Exosomes were isolated from the aforementioned cell lines, with the goal of doing a molecular profile 
of these exosomes in order to find a signature that could be indicative of response to therapy. In terms 
of exosome isolation, the most common isolation method is differential ultracentrifugation, and even 
though this procedure was used, it is important to understand that there is no protocol that solely 
isolates exosomes. It should always be taken into account that in one isolation, mostly exosomes and 
microvesicles will be present, but also other types of EVs (Raposo and Stoorvogel, 2013). Plus, it is also 
important that the conditions in which the cells that are going to secrete exosomes grow are the same. 
Because if for example the conditions are changed, cells will not only alter their transcriptional 
program, and therefore change what will be packaged in these vesicles, but if they are too confluent 
they will also start secreting more and more apoptotic bodies, which leads to a poorer yield in terms of 
exosome isolation. All these things need to be taken into consideration when isolating exosomes, since 
one isolation is formed of many different subpopulations of exosomes and other vesicles, and it is 
crucial to have a standard procedure so that subsequent experiments might be reproducible. 
 
Therefore, the next step is always to assess the quality of the EV/exosome isolation. In order to 
properly characterize an exosome isolation, it is important to use and complement different molecular 
techniques that will give you different outputs. Some examples are transmission electron microscopy 
(TEM), Nanoparticle tracking analysis for size distribution and relative concentration, and western 
blot to check for the presence of common exosomal markers. Since exosomes are known to float at 
densities between 1.13 and 1.19 g/mL, linear sucrose gradients can be used to further purify the 
exosome isolation, but this greatly reduces the amount of available sample. 
 
By complementing these techniques we characterized our isolated exosomes, and in Figure 3.1 and 
3.2, both DU145 and DUR exosomes present the characteristic "cup-shaped" form as seen by TEM, 
and show a typical size distribution of these vesicles, with DU145 exosomes showing 120 nm of 
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diameter in average, and DUR exosomes 100 nm diameter in average. Besides, both DU145 and DUR 
exosomes show the typical exosomal markers by western blot, with or without purification by linear 
sucrose gradient. NTA analysis of the different fractions reinforces these observations, as most 
particles are in the exosome density range. 
 
The same principles were used on exosomes isolated from DUAAR; LNCaP and LNAAR cells, as 
observed in Figures 3.7 and 3.8, with slight variations, for example in the exosomal markers evaluated. 
In this case though, both DU145 and DUAAR exosomes show most of the particles having diameters 
of around 120 nm, while LNAAR and LNCaP exosomes present most particles having diameters of 
110 nm. An interesting finding, which can be seen in Figure 3.1C and 3.7B, is that all resistant cell 
lines in study seem to secrete more exosomes than their sensitive counterparts. For the DUR cells this 
is particularly striking, as Docetaxel targets the microtubule, and it is known that they regulate 
vesicular trafficking, which in turn is related to exosome secretion (Zhang et al., 2015). But since the 
same is observed with DUAAR and LNAAR cells, it can be assumed that more generalized 
mechanisms are also involved, one that could have been acquired concomitantly with resistance to 
therapy as some sort of defence mechanism. 
 
By looking at Figures 3.1D, 3.3, 3.4B, 3.8A, 3.9 and 3.10, for example, it is easy to understand that 
exosomes are enriched in certain proteins (CD82 in the DUR exosomes, TSG101 in the LNAAR 
exosomes, among other examples), not only compared to the cells they are originated from, but also 
between exosomes from the resistant and sensitive cell lines. This shows that these cell lines differ not 
only in terms of the amount of secreted vesicles, but also in terms of physical characteristics, which 
are then reflected on the respective exosomes, and those subtle changes might have an impact on the 
recipient cells that uptake these exosomes. 
 
Another interesting result was the one observed in Figure 3.4B. Focusing on the MDR-1, it appears 
that DUR exosomes are the only ones to have p-glycoprotein in their cargo. This glycoprotein, 
member of the ABCB1 superfamily of transporters, is located on the cell surface and is as a drug 
efflux pump, ATP-dependant, and is involved in a non-specific mode of resistance to chemotherapy. 
We speculate that DUR exosomes loaded with p-gp act as a systemic defence mechanism by uptaking 
unbound Docetaxel, therefore excreting it from the cell along with the exosomes. A study from this 
year performed by Kato et al. show that exosomal p-gp is a potential marker for response to Docetaxel 
therapy in the prostate cancer setting (Kato et al., 2015). 
 
In an attempt to correlate a recent study performed by Antonarakis et al. in circulating tumour cells, 
where they show that the splice variant 7 of the androgen receptor (AR-V7) is a predictive biomarker 
of response to AA and Enzalutamide, we show a western blot image of DU145 and LNCaP, cells and 
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exosomes, sensitive and resistant to AA, probed for the androgen receptor. It appears that only the 
LNCaP and LNAAR cells show a clear band of the full length androgen receptor (AR-FL) at around 
110 kDa, which is expected since DU145, and consequently DUAAR, are androgen receptor null. This 
doesn't mean however that these cells don't express other splice variants, among them the AR-V7. This 
splice variant lacks the ligand binding domain where testosterone and DHT bind, but can still 
translocate to the nucleus and act as a transcription factor for androgen responsive genes, potentially 
conferring resistance to ARAT drugs such as AA and Enza. The antibody used is not specific for the 
AR-V7, but still detects it at around 75 kDa. It just can't distinguish it from other splice variants (SVs), 
and in the image shown, DUAAR exosomes seem to have higher abundance of these AR-SVs when 
compared to DU145 cells. If a percentage of the SVs that appear to be present in the DUAAR 
exosomes were indeed AR-V7, this could indicate that not only CTCs, but also exosomes that are AR-
V7 positive, could act as predictive biomarkers of response to AA and Enza therapies. 
 
In sum, we have isolated and characterized exosomes derived from prostate cancer cell lines that are 
resistant to Docetaxel and Abiraterone Acetate. Proteomics analysis was performed on these 
exosomes, as compared to exosomes isolated from the same cell lines but not resistant to the drugs in 
this study, and the goal is to identify potential biomarkers that are predictive of response to therapy. 
For that matter, we propose p-gp positive exosomes as a candidate biomarker for response to 
Docetaxel, and AR-V7 positive exosomes as predictive biomarkers of response to both Abiraterone 
Acetate and Enzalutamide. Both of these candidates require further validation.  
 
In the near future, the objective is to conclude the proteomics approach on the Abiraterone Acetate 
study, and try to identify a predictive signature of response to Abiraterone. In addition, we will try to 
incorporate other kinds of approaches, including mRNA and miRNA arrays, in order to account for 
most of the bioactive molecules present in the exosomes. Another interesting way to use our model 
would be to address the metastatic potential and try to identify characteristic biomarkers, as DU145 is 
a highly metastatic cell line and LNCaP has lower metastatic potential. In summary, the ultimate the 
goal is to provide a more stratified strategy of treatment in the clinic, leading to a more personalized 
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